Kornimate/medical-research-clean huggingface dataset:
characteristics and outcomes of childhood moyamoya in the uk

Conditions: Moyamoya

Summary: this is a study to ascertain the number of children with moyamoya in the uk, their presenting features, clinical course and outcomes.

the study ahs 3 components: 1. patient identification via the british paediatric surveillance unit, and the 21 collaborating centres 2. record review/patient interview to determine clinical features \& outcomes 3. centralised review of imaging data to ascertain radiological phenotypes

Eligibility criteria:
inclusion criteria: * radiological diagnosis of moyamoya exclusion criteria: * refuse consent
phase 3 study of pelubiprofen tab. & celebrex cap. in rheumatoid arthritis patients

Conditions: Pelubiprofen; Celebrex; Rheumatoid Arthritis

Summary: a randomized, double-blind, multicenter, phase 3 study of pelubiprofen tab. \& celebrex cap. for comparative evaluation of safety \& efficacy in rheumatoid arthritis patients


Eligibility criteria:
inclusion criteria: 1. adult males/females aged 18\~80 years 2. patient who are taking nsaids for the treatment of rheumatoid arthritis 3. patients who belong to acr functional class 1, 2, 3 exclusion criteria: 1. patients who belong to acr functional class 4 2. patients who are hypersensitive to clinical trial medicines or excipient 3. patients who have experience of cerebrovascular bleeding, bleeding disorder
robot-based therapy for upper limb sensorimotor impairments after stroke

Conditions: Stroke

Summary: after a stroke, more than two out of three patients experience problems with upper limb movement and sensation. current evidence on treatment of upper limb sensory impairments is scarce and shows unclear results. robot-based therapy has been increasingly used to treat upper limb motor impairments, with similar positive results as compared to conventional therapy. this study aims to investigate a novel robot-based therapy program for treatment of upper limb sensory impairments. the therapy program consists of 10 one-hour session spread over 4 weeks and will be evaluated for its effect in 20 chronic stroke patients. the investigators hypothesize that a 4-week robot-based therapy program can improve upper limb sensation and movement.

up to 70% of stroke survivors show upper limb impairments consisting of motor and/or somatosensory impairments. these impairments often persist well into the chronic stage, and may lead to significant limitations in activities of daily living and may negatively affect quality of life. different interventions have been investigated to treat upper limb motor impairments, including robot-based therapy, which shows similar positive results as compared to conventional therapy. evidence on interventions for somatosensory impairments is scarce and often of low quality. this study therefore aims to evaluate the effect of a robot-based therapy program on sensorimotor function of the upper limb in a group of 20 chronic stroke patients. the robot-based therapy will be provided using the kinarm end-point lab (bkin technologies ltd., canada) and consists of passive and active therapy tasks for proprioception and sensory processing. the therapy consists of 10 one-hour sessions spread over 4 weeks. clinical and robot-based motor and somatosensory assessments will be performed at 4 time points: twice at baseline, once at mid intervention, and once after 10 hours of therapy. the investigators hypothesize to find improvement in both upper limb motor and somatosensory function after the therapy program. the results from this pilot study will provide a basis for further research.

Eligibility criteria:
inclusion criteria: * at least 18 years old * a first-ever unilateral, supratentorial stroke (as defined by who) * in the chronic phase after stroke (i.e. being at least 6 months after stroke) * motor deficits of the upper limb (fugl-meyer motor assessment - upper extremity \< 60/66) * somatosensory deficits of the upper limb (erasmus modified nottingham sensory assessment \< 36/40) * ability to perform, at least to some extent, active shoulder abduction and wrist extension against gravity * ability to perform passive and active sensory processing assessment task (primary outcome measure) exclusion criteria: * history of previous stroke or tia * any serious musculoskeletal and/or other neurological conditions * serious communication or cognitive deficits * no written informed consent

Keywords: stroke upper limb somatosensation sensory processing proprioception robot-based therapy robot-based assessment
whole body vibration training for diabetic patients with burn injury

Conditions: Burn Injury

Summary: burn injury as well as diabetes mellitus (dm) induce physical functional and psychological impairments. lower limb burn involving foot are still a challenging heath condition because of its important sensory role. balance is disturbed either in patients with lower limb burn injury or diabetic patients. this study aime to compare between the effects whole body vibrational training and yoga exercises on postural balance, and activities-specific balance confidence in in type ii diabetic patients with foot burn

thirty eight diabetic patients (17 male, 21female) with foot burn injury, with their age ranged from 40 to 55 years. they will randomly assigned into two equal groups. group (a) will receive low vibrational training in the form of whole body vibration for 8 weeks (n=19), while group (b) the control group for 8 weeks (n=19) in addition both groups will receive their routine medical care and physical therapy rehabilitation including balancing exercises. dynamic balance will be evaluated through biodex balance system (bbs);and balance confidence will be measured by the activities-specific balance confidence scale (abc) before the starting and after the end of treatment for all patients in both groups

Eligibility criteria:
inclusion criteria: * chronic lower limb burns injury for more than 6 months * total body surface area (tbsa) burnt ≤ 30%.; exclusion criteria: * cognitive or mentality dysfunctions, * psychiatric conditions, * fractures, * pregnancy, * cancer, * severe vascular complications, * inability to walk
benefits of telemedicine in cpap treatment

Conditions: Obstructive Sleep Apnea

Summary: continuous positive airway pressure (cpap) is the first choice of treatment for moderate to severe obstructive sleep apnea syndrome (osas). although adherence is critical for achieving a good treatment effect, and early intervention if treatment problems emerge is important for achieving good adherence, information on patient compliance is usually based on assessment of the first few weeks of treatment. telemedicine technology allows for monitoring of cpap pressure, air leaks, apnea-hypopnea index (ahi) and compliance on a daily basis and could therefore be an option allowing for adequate support and quick response if a patient has problems with the treatment. in addition, improving early experiences of cpap, identifying patients in need of more intensive support could potentially improve adherence but also reduced cost of care, and increased patient satisfaction. the proposed study will recruit 200 osas patients starting cpap treatment; 100 patients randomized to afterwards receiving telemonitoring in combination with telephone calls, and 100 patients randomized to receiving usual office visits. all patients will in addition answer questionnaires on sleep and health, quality of life, and patient satisfaction after the first cpap information visit and then again after 6 months of treatment. at time of follow-up all patients will also answer questionnaires on side effects of cpap. health economic variables will also be measured throughout the testing period. the study will provide valuable information regarding benefits of telemonitoring in clinical work with cpap therapy. implementation of telemedicine-based monitoring of cpap therapy may be an important part of increasing adherence among patients but also in the development of a more cost-effective care as it can provide clinics with increased treatment capacity and follow-up of both new and established patients. it would further improve the care for these patients who often have a lifelong treatment, which aims to reduce the risk of developing cardiovascular disease or premature death.


Eligibility criteria:
inclusion criteria: * patients diagnosed with osa and scheduled to receive cpap treatment exclusion criteria: * patients not understandning swedish * patients not eligible for cpap start within a group session.

Keywords: obstructive sleep apnea continuous positive airway pressure telemoedicine
efficacy and safety of impracor (ketoprofen 10% cream) compared with placebo in the treatment of acute pain (flare) associated with osteoarthritis of the knee

Conditions: Acute Pain (Flare) Associated With Osteoarthritis (OA) of the Knee

Summary: the primary objective of the study is to assess analgesic efficacy of impracor (ketoprofen 10% cream) compared to placebo for acute pain associated with oa flare of the knee.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of oa of the knee according to the acr criteria. * kellgren-lawrence grade 2-3 disease * be willing to stop taking all analgesics including nsaids and opioids for the duration of the study, with exception of study-specified rescue medication. exclusion criteria: * total knee replacement surgery tentatively scheduled within next 6 months. * palpable knee effusion. * significant pain outside the target knee, including significant hip, back, or contralateral knee pain. * any type of orthopedic and/or prosthetic device or any skin abnormalities on the target knee that would prevent evaluations of local tolerability. * history of asthma, rheumatoid arthritis, chronic inflammatory disease (e.g., colitis), or fibromyalgia. * history of gastrointestinal bleeding or peptic ulcer disease within the past 3 years. * have a positive urine drug test for illegal drug substances, non-prescribed controlled substances, or alcohol at screening. * acute or chronic illness that in the opinion of the investigator could compromise the integrity of study data or place the subject at risk by participating in the study.
aveir dr i2i study

Conditions: Cardiac Pacemaker, Artificial; Cardiac Rhythm Disorder; Bradycardia

Summary: prospective, non-randomized, multi-center, international study designed to evaluate the safety and effectiveness of the aveir™ dual-chamber (dr) leadless pacemaker system.

the purpose of this clinical investigation is to evaluate the clinical safety and effectiveness of the aveir dr leadless pacemaker system in a patient population indicated for a ddd(r) pacemaker. subjects participating in the study are followed through at least 12 months with data collected at baseline, implant procedure, pre (hospital) discharge, and follow-up at 1 month, 3 months, 6 months, 12 months, and every 6 months thereafter until study completion

Eligibility criteria:
inclusion criteria: 1. subject must have at least one of the clinical indications before device implant in adherence with acc/aha/hrs/esc dual chamber pacing guidelines 2. subject is ≥ 18 years of age or age of legal consent, whichever age is greater 3. subject has a life expectancy of at least one year 4. subject is willing to comply with clinical investigation procedures and agrees to return to clinic for all required follow-up visits, tests, and exams 5. subject has been informed of the nature of the clinical investigation, agrees to its provisions and has provided a signed written informed consent, approved by the irb/ec exclusion criteria: 1. subject is currently participating in another clinical investigation that may confound the results of this study as determined by the sponsor 2. subject is pregnant or nursing and those who plan pregnancy during the clinical investigation follow-up period 3. subject has presence of anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could confound the assessment of the investigational device and/or implant procedure, limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements of the clinical investigation results 4. subject has a known allergy or hypersensitivity to \< 1 mg of dexamethasone sodium phosphate or any blood or tissue contacting material listed in the ifu 5. subject has an implanted vena cava filter or mechanical tricuspid valve prosthesis 6. subject has pre-existing, permanent endocardial pacing or defibrillation leads (does not include lead fragments) 7. subject has current implantation of either conventional or subcutaneous implantable cardioverter defibrillator (icd) or cardiac resynchronization therapy (crt) device 8. subject has an implanted leadless cardiac pacemaker (except for an aveir ventricular leadless pacemaker) 9. subject is implanted with an electrically-active implantable medical device with stimulation capabilities (such as neurological or cardiac stimulators) 10. subject is unable to read or write

Keywords: bradycardia sick sinus syndrome pacemaker av block vasovagal syncope
establishment of a primary epididymal cell model from epididymal samples to study cftr gene regulation

Conditions: Cystic Fibrosis; Congenital Bilateral Absence of Vas Deferens; Sterility, Male

Summary: the aim of this observational study is to better understand the role and involvement of the regulatory elements of the cftr gene, with the aim of better describing the 3d organisation of chromatin at the cftr locus in epididymal cells in patients with male infertility of any kind, or with cystic fibrosis or bilateral agenesis of the vas deferens, requiring scheduled surgery. the main questions it aims to answer are: * to better characterise this 3d organisation of the cftr locus, the study of regulatory elements in primary epididymal cells is the most relevant and realistic model. * to gain a better understanding of the regulation of the cftr gene in epididymal cells in order to gain a better understanding of the pathology of male infertility caused by bilateral agenesis of the vas deferens, a symptom and also a borderline form of cystic fibrosis. participants will epididymal samples will be taken by a urologist for the amp department during the planned surgery. the rest of the samples taken will be recovered for research purposes, with the aim of recovering the epididymal cells contained in the sample. this is in no way an additional procedure and will have no impact on the patient's health..


Eligibility criteria:
inclusion criteria: * male patients over 18 years of age * patients, without genetic pathology, scheduled for epididymal sampling surgery * patients with cystic fibrosis or bilateral vas deferens agenesis, scheduled for epididymal sampling surgery. * signature of a consent form exclusion criteria: * patients not scheduled for epididymal harvesting surgery * patients under legal protection (guardianship, curatorship) * refusal to participate

Keywords: infertility primary epididymal cells
incidence of popf in the resection of the left pancreas with rfat

Conditions: Pancreas Neoplasm; Pancreas Cancer; Pancreatic Adenocarcinoma; Benign Pancreas Tumor

Summary: this study evaluates the impact of the radiofrequency assisted transection on the rate of postoperative pancreatic fistula (popf) after performing distal pancreatectomies, central pancreatectomies and pancreatic enucleation

among the different methods for sealing the remaining pancreas, resection and sealing devices assisted by radiofrequency energy (rf) have been used, both in experimental studies and in clinical trials, in order to try to reduce the popf rate. one of these devices is the coolinside®, which is approved for this indication and is currently used in selected cases, at the hospital del mar, among other centers. although there are several published studies based on similar technology, the existing publications on the use of coolinside® in the pancreas have been made in rat and pig animal models. in particular, the most recent study published by dorcaratto et al. compares the coolinside device vs. the mechanical stapler in porcine model when performing distal pancreatectomies. the results suggest that the coolinside device was more efficient in the control of the popf than the stapler with a popf index of 12% vs. 36%. therefore, this study aims to obtain more clinical evidence about the use of coolinside in pancreatic resections within a clinical context.

Eligibility criteria:
inclusion criteria: * patients with benign or malignant lesions of the pancreas * subjected to distal, central pancreatectomy or enucleations of the left pancreas * patients asa (american society of anesthesiologists i-iii * open or laparoscopic approach. exclusion criteria: * asa ≥iv patients * patients with limitrophic or neuroendocrine lesions
multicenter retrospective observational study of acute myocarditis in korea

Conditions: Myocarditis Acute

Summary: in this study, the investigators analyze the clinical characteristics and prognosis of patients with acute myocarditis in south korea

acute myocarditis refers to a condition in which inflammatory cells infiltrate the heart muscle due to various causes. until now, there is no clear treatment method for myocarditis itself, and when myocardial function deteriorates or arrhythmia occurs due to myocarditis, it is common to wait for natural recovery while performing general supportive treatment for heart failure. through this study, the investigators analyze the factors contributing to the long-term prognosis, myocardial recovery rate, and clinical course of myocarditis. and, the investigators plan to establish an appropriate treatment strategy necessary to increase the survival rate of patients with myocarditis.

Eligibility criteria:
inclusion criteria: * typical myocarditis symptom and sign, such as fever, chest pain, chest discomfort or shortness of breath, accompanied by elevated myocardial enzymes * the above condition is satisfied and additional information is obtained through imaging such as cardiac mri or cardiac biopsy exclusion criteria: ● coronary artery disease
autologous implantation of mesenchymal stem cells for the treatment of distal tibial fractures

Conditions: Tibial Fracture

Summary: mesenchymal stem cells are found in bone marrow, and have the ability to differentiate into different tissue types. the primary objective of the study is to examine the safety of using such cells to treat patients suffering from distal tibial shaft fractures. the cells will be isolated from the patient's bone marrow, loaded onto a carrier and implanted locally at the fracture site.


Eligibility criteria:
inclusion criteria: * ages 18 and 65. males not involved in active military duty. females- non child bearing potential. distal tibia third fracture without joint involvement. fracture treated by im nail, percutaneous plating or external fixation. exclusion criteria: * active systemic or local infection. history of malignancy radiotherapy or chemotherapy. active autoimmune disease. any past or present immunosuppressive treatment. fracture treated by open reduction. fracture grade gustillo grade iiib, iic. use of steroids in past 6 months. chronic renal insufficiency. administration of marrow suppressive drugs. history of metabolic bone disease. administration of drugs that may interfere with bone metabolism.
the effects of gip and glp-2 on the secretion of glucagon in patients with type 1 diabetes

Conditions: Diabetes Mellitus

Summary: the purpose of this study is to determine whether glucose-dependent insulinotropic polypeptide (gip) or glucagon like peptide 2 (glp-2) has an affect on the secretion of glucagon from the pancreas in patients with type 1 diabetes mellitus.


Eligibility criteria:
inclusion criteria: * caucasians over 18 years with type 1 diabetes (who criteria) * arginine test without rise in plasma c-peptide * normal blood hemoglobin * informed consent exclusion criteria: * liver disease * diabetic nephropathy * treatment with medications unpausable for 12 hours

Keywords: glucagon glucose-dependent insulinotropic polypeptide glucagon-like peptide 2
multi-level hiv prevention for pregnant drug abusers

Conditions: Substance Related Disorders

Summary: this 5 year study, targeting pregnant drug abusers in treatment, is a randomized trial of an enhanced behavioral skills training (e-bst) intervention compared to a time-and attention-matched health promotion comparison (hpc) condition. e-bst is an adaptation of the original bst intervention (eldridge, st. lawrence et al., 1997), designed to strengthen relationship-based social competency skills of the original bst that were crucial in sustaining adherence to protective behavior.


Eligibility criteria:
inclusion criteria: * 18 years of age or older * a recent history (within the past year) of using illicit substances * 12-32 weeks pregnant and not planning to terminate the pregnancy * able to read english informed consent form; understand and provided written informed consent * have competency in conversational english which is required to complete assessments and to participate in the intervention groups * have a stable living arrangement and provide contact information * currently not cognitively impaired since cognitive impairment may compromise the ability to comprehend and participate in the assessment and intervention * currently not showing symptoms of a major psychiatric disorder/ including psychosis, or a high risk for suicidality * report at least one episode of unprotected vaginal/anal sex since becoming pregnant * answer "yes" to this question: "do you plan to be in the area for the next 12 months?" * agree to a urine test at the time of each interview to detect the presence of drugs exclusion criteria: * under age 18 years

Keywords: hiv risk behaviors pregnant drug abusers
a trial of tt223 in patients with type 2 diabetes who are taking metformin and/or thiazolidinedione

Conditions: Diabetes Mellitus, Type 2

Summary: this trial is designed to show the effect of treatment with tt223 or placebo on blood glucose control after 12 weeks of treatment with a 6 month follow-up. tt223 is administered by injection once daily to patients currently treated with metformin and/or thiazolidinedione.


Eligibility criteria:
inclusion criteria: * type 2 diabetes for at least 6 months * treated with metformin and/or thiazolidinediones with stable dose for at least 3 months * bmi of 21-45 kg/m2, inclusive * hba1c level of 7.50 - 10.00%, inclusive * if a female of childbearing potential, willing to utilize contraception from screening through 4 weeks after the last dose of study drug exclusion criteria: * treatment with insulin, sulfonylurea, dpp-4 inhibitors, symlin® and/or glp-1 analogues ≤ 3 months prior to the screening * severe hypoglycemia ≤ 60 days prior to the screening visit or currently diagnosed with having hypoglycemia unawareness * history of peptic ulcer(s) and/or gastrointestinal bleeding/perforation * previous gastric surgery, including gastric bypass, or has gastric bypass/other major surgery planned to occur during the 10 month trial * myocardial infarction within the last 2 years, current congestive heart failure with nyha class 2 or greater, or chronic atrial fibrillation * current clinically significant and/or chronic illness * takes regular courses of non-steroidal anti-inflammatory drugs (nsaids). if these medications are discontinued upon starting screening procedures and are not planned to be regularly used during the trial, the patient will be allowed to enter the study * use of systemic corticosteroids (oral, suppository, injected). use of inhaled or topical corticosteroids is permitted

Keywords: tt223